SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is facing significant investor uncertainty and downward pressure following news that a co-founder, a board member, and other personnel were indicted in an alleged conspiracy to smuggle high-performance chips to China. While the company stated it is not named as a defendant and is cooperating with investigators, community discussion is dominated by concerns regarding the company's internal compliance, the stability of its critical relationship with partners like Nvidia, and ongoing leadership controversies.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending following a record-breaking earnings beat and strong forward guidance, fueled by surging defense demand and institutional interest in the space sector. The community is actively discussing the stock's potential for further gains, comparing it to other space sector leaders and debating the impact of government contracts on its long-term growth.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is capturing attention as community members debate its long-term potential ahead of the Super App launch and high-profile industry events like the upcoming XRP Las Vegas conference. Investors are actively discussing the impact of imminent token unlocks, upcoming institutional partnerships, and the project's push into real-world payment infrastructure as they weigh the risks and rewards of accumulating at current levels.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending following a massive $1.25 billion deal with Uber to deploy up to 50,000 autonomous R2 robotaxis by 2031, which is fueling intense community debate regarding the company's long-term execution capabilities and path to profitability. While many investors are celebrating this strategic partnership as a major validation of Rivian's platform, others remain skeptical, pointing to the long timeline for deployment and ongoing concerns about production scale and cash burn.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is currently seeing extreme volatility and heightened investor scrutiny as traders debate whether its recent parabolic move is a sustainable play on the indium phosphide supply chain bottleneck or an unsustainable pump-and-dump. While bullish investors point to its critical role in the optical infrastructure required for AI data centers, skeptics are actively targeting the stock, citing aggressive insider selling, an underwhelming revenue-to-market-cap ratio, and the constant threat of a dilutive equity offering.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is attracting significant investor attention following a solid earnings beat and raised full-year guidance, with the community actively debating the impact of the planned Freight business spin-off and broader shipping demand. While bullish participants point to disciplined cost-cutting and domestic growth as key drivers, skeptics are expressing caution regarding geopolitical risks and potential margin pressure from volatile fuel and freight costs.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines ($UMAC) is under intense scrutiny following the announcement of a new public offering, which the community is heavily debating as a dilutive move despite the company's positioning within the government-backed drone manufacturing sector. Investors are actively analyzing the stock's long-term potential tied to U.S.-based defense contracts and its connections to high-profile political figures, leading to polarized discussions between those viewing the price dip as a strategic entry point and others wary of the company's history of recurring share offerings.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors await the final analysis of its pivotal Phase 3 REGAL trial, with community discussion intensely focused on whether the lack of an 80th-event announcement signals durable patient survival indicative of a curative breakthrough. While some traders are expressing skepticism over the timeline and lack of recent conference calls, many longs are highlighting the company's strong cash position and the potential for a transformative valuation re-rating if the trial data succeeds.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

The Defiance Daily Target 2X Long SMCI ETF is facing extreme volatility and selling pressure as investors struggle with the compounding impact of decay and a sharp downtrend in the underlying stock. The community remains heavily divided between those aggressively averaging down in anticipation of a potential short squeeze or technical reversal, and those who are cutting losses to avoid further risks from reverse splits and persistent downward price action.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals is trending due to the FDA's approval of an expanded indication for IMCIVREE, allowing the treatment of patients as young as two years old. The community is actively discussing the potential revenue growth from this label extension, the company's strong clinical pipeline, and ongoing speculation regarding its long-term potential as a key acquisition target in the rare disease space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$MBRX ​​MBRX Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

ELITE_MOMENTUM_TRADING

Kelly Mone

StockTwits Web

Moleculin Biotech Inc

 ​​MBRX Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026